RLMD
Relmada Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$759.40M
P/E Ratio
—
EPS
$-1.45
Beta
0.83
52W High
$7.94
52W Low
$0.32
50-Day MA
$6.12
200-Day MA
$3.48
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to treat central nervous system (CNS) diseases and other disorders in the United States. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-13.86M |
| Operating Margin | 0.00% |
| Return on Equity | -25.60% |
| Return on Assets | -14.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.18 |
| Price-to-Book | 8.78 |
| Price-to-Sales (TTM) | 9001.90 |
| EV/Revenue | 7110.5 |
| EV/EBITDA | 0.54 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $104.89M |
| Float | $7.72M |
| % Insiders | 7.52% |
| % Institutions | 51.20% |
Analyst Ratings
Consensus ($12.80 target)
1
Strong Buy4
BuyData last updated: 4/29/2026